Niagen Bioscience, Inc. Common Stock NAGE Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $130.42M+0.8% | $129.42M+3.8% | $124.71M+7.2% | $116.3M+7.8% | $107.93M+8.4% | ||
| $46.58M+0.8% | $46.23M+2.7% | $45.03M+6.4% | $42.31M+4.6% | $40.46M+6.5% | ||
| $83.83M+0.8% | $83.19M+4.4% | $79.68M+7.7% | $73.99M+9.7% | $67.46M+9.5% | ||
| 64.3%0.0pp | 64.3%+0.4pp | 63.9%+0.3pp | 63.6%+1.1pp | 62.5%+0.7pp | ||
| $6.55M+3.5% | $6.33M+6.7% | $5.94M+9.3% | $5.43M+4.8% | $5.18M-13.9% | ||
| $37.06M+4.4% | $35.51M+5.0% | $33.81M+5.4% | $32.08M+4.0% | $30.85M+4.7% | ||
| $29.12M+7.6% | $27.06M+31.1% | $20.64M+4.2% | $19.81M+8.8% | $18.21M-0.9% | ||
| $70.75M+5.7% | $66.91M+10.8% | $60.38M+5.3% | $57.32M+5.7% | $54.23M+0.7% | ||
| $13.08M-19.6% | $16.28M-15.7% | $19.3M+15.8% | $16.67M+26.0% | $13.23M+71.2% | ||
| 10%-2.5pp | 12.6%-2.9pp | 15.5%+1.1pp | 14.3%+2.1pp | 12.3%+4.5pp | ||
| $1.83M-4.4% | $1.91M-1.8% | $1.95M+17.3% | $1.66M+23.1% | $1.35M+19.5% | ||
| $19.7M+8.3% | $18.19M-14.4% | $21.25M+15.9% | $18.33M+25.7% | $14.58M+64.6% | ||
| $1.06M+30.7% | $810K-1.6% | $823K+36.9% | $601K+27.1% | $473K+55.1% | ||
| $18.64M+7.2% | $17.38M-14.9% | $20.43M+15.2% | $17.73M+25.7% | $14.11M+65.0% | ||
| 14.3%+0.9pp | 13.4%-3.0pp | 16.4%+1.1pp | 15.2%+2.2pp | 13.1%+4.5pp | ||
| $0.21+5.0% | $0.20-16.7% | $0.24+14.3% | $0.21+23.5% | $0.17+70.0% | ||
| $13.96M-18.2% | $17.06M-15.0% | $20.08M+15.1% | $17.45M+24.5% | $14.02M+64.2% | ||
| 10.7%-2.5pp | 13.2%-2.9pp | 16.1%+1.1pp | 15%+2.0pp | 13%+4.4pp | ||
| $13.08M-19.6% | $16.28M-15.7% | $19.3M+15.8% | $16.67M+26.0% | $13.23M+71.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Niagen Bioscience, Inc. Common Stock's revenue?
- Niagen Bioscience, Inc. Common Stock (NAGE) generated $130.4M in revenue over the trailing twelve months, up 20.8% year over year.
- Is Niagen Bioscience, Inc. Common Stock profitable?
- Niagen Bioscience, Inc. Common Stock reported $18.6M in net income over the trailing twelve months, a 14.3% net margin.
- What are Niagen Bioscience, Inc. Common Stock's profit margins?
- Gross margin is 64.3% and operating margin is 10.0%, with a 14.3% net margin.
- What is Niagen Bioscience, Inc. Common Stock's earnings per share?
- Niagen Bioscience, Inc. Common Stock's diluted EPS over the trailing twelve months is $0.21.
- Where does Niagen Bioscience, Inc. Common Stock's income statement data come from?
- Every line is extracted from Niagen Bioscience, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
